Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Investing Activities (2021 - 2025)

ARS Pharmaceuticals' Cash from Investing Activities history spans 5 years, with the latest figure at $24.1 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 123.7% year-over-year to $24.1 million; the TTM value through Dec 2025 reached $56.8 million, up 153.5%, while the annual FY2025 figure was $56.8 million, 153.5% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $24.1 million at ARS Pharmaceuticals, up from -$45.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $48.6 million in Q2 2025 and bottomed at -$111.5 million in Q1 2023.
  • The 5-year median for Cash from Investing Activities is -$32500.0 (2021), against an average of -$6.8 million.
  • The largest YoY upside for Cash from Investing Activities was 204509.09% in 2023 against a maximum downside of 531071.43% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at $40.7 million in 2021, then plummeted by 100.31% to -$126000.0 in 2022, then surged by 20765.87% to $26.0 million in 2023, then plummeted by 490.8% to -$101.8 million in 2024, then soared by 123.7% to $24.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Cash from Investing Activities are $24.1 million (Q4 2025), -$45.0 million (Q3 2025), and $48.6 million (Q2 2025).